JPWO2020124273A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020124273A5 JPWO2020124273A5 JP2021535804A JP2021535804A JPWO2020124273A5 JP WO2020124273 A5 JPWO2020124273 A5 JP WO2020124273A5 JP 2021535804 A JP2021535804 A JP 2021535804A JP 2021535804 A JP2021535804 A JP 2021535804A JP WO2020124273 A5 JPWO2020124273 A5 JP WO2020124273A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleotide sequence
- promoter
- seq
- cancer
- transgene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862784372P | 2018-12-21 | 2018-12-21 | |
| US62/784,372 | 2018-12-21 | ||
| US201962872699P | 2019-07-10 | 2019-07-10 | |
| US62/872,699 | 2019-07-10 | ||
| US201962930524P | 2019-11-04 | 2019-11-04 | |
| US62/930,524 | 2019-11-04 | ||
| PCT/CA2019/051898 WO2020124273A1 (en) | 2018-12-21 | 2019-12-20 | Modified orthopoxvirus vectors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022514420A JP2022514420A (ja) | 2022-02-10 |
| JPWO2020124273A5 true JPWO2020124273A5 (https=) | 2023-01-04 |
| JP2022514420A5 JP2022514420A5 (https=) | 2023-01-04 |
Family
ID=71100021
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021535833A Pending JP2022516006A (ja) | 2018-12-21 | 2019-12-20 | 修飾オルソポックスウイルスベクター |
| JP2021535804A Pending JP2022514420A (ja) | 2018-12-21 | 2019-12-20 | 修飾オルソポックスウイルスベクター |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021535833A Pending JP2022516006A (ja) | 2018-12-21 | 2019-12-20 | 修飾オルソポックスウイルスベクター |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20220380799A1 (https=) |
| EP (2) | EP3898997A4 (https=) |
| JP (2) | JP2022516006A (https=) |
| KR (2) | KR20210132003A (https=) |
| CN (2) | CN113661246A (https=) |
| AU (2) | AU2019410148A1 (https=) |
| BR (2) | BR112021012078A2 (https=) |
| CA (2) | CA3124287A1 (https=) |
| CL (1) | CL2021001646A1 (https=) |
| CO (1) | CO2021009354A2 (https=) |
| EC (1) | ECSP21053474A (https=) |
| IL (2) | IL284180A (https=) |
| MX (2) | MX2021007439A (https=) |
| PE (1) | PE20212307A1 (https=) |
| PH (1) | PH12021551436A1 (https=) |
| SG (1) | SG11202106460XA (https=) |
| TW (1) | TW202039851A (https=) |
| WO (2) | WO2020124274A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3778881A1 (en) | 2016-01-08 | 2021-02-17 | Replimune Limited | Modified oncolytic virus |
| US12350303B2 (en) | 2017-02-03 | 2025-07-08 | University of Pittsburgh—of the Commonwealth System of Higher Education | Oncolytic virus therapy |
| MX2020007010A (es) | 2018-01-05 | 2020-12-10 | Ottawa Hospital Res Inst | Vectores modificados de orthopoxvirus. |
| WO2021102307A1 (en) * | 2019-11-20 | 2021-05-27 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Vaccinia viruses and methods for using vaccinia viruses |
| JP6915792B1 (ja) * | 2020-10-01 | 2021-08-04 | 国立大学法人鳥取大学 | 広範囲遺伝子欠損を有する腫瘍溶解性ワクシニアウイルス |
| WO2023106839A1 (ko) * | 2021-12-07 | 2023-06-15 | 재단법인 아산사회복지재단 | Il-12를 발현하는 재조합 백시니아 바이러스 및 이의 용도 |
| AU2023207821A1 (en) * | 2022-01-17 | 2024-09-05 | Nouscom Ag | Recombinant orthopox viral vector encoding immunostimulatory proteins for cancer treatment |
| CN119677861A (zh) * | 2022-06-10 | 2025-03-21 | 特兰斯吉恩股份有限公司 | 表达白介素-12的重组病毒 |
| CA3260631A1 (en) * | 2022-07-08 | 2024-01-11 | Viromissile, Inc. | Oncolytic and recombinant vaccine viruses and their methods of use |
| KR20250044313A (ko) * | 2022-07-27 | 2025-03-31 | 아스트라제네카 아베 | Pd-1/pd-l1 저해제와 인터루킨-12를 발현하는 재조합 바이러스의 조합물 |
| CN115947797B (zh) * | 2022-08-02 | 2024-07-05 | 青岛硕景生物科技有限公司 | 猴痘病毒重组抗原及其应用 |
| WO2024130212A1 (en) | 2022-12-16 | 2024-06-20 | Turnstone Biologics Corp. | Recombinant vaccinia virus encoding one or more natural killer cell and t lymphocyte inhibitors |
| CN115927215B (zh) * | 2023-01-18 | 2025-10-17 | 中国医学科学院病原生物学研究所 | 一种定向减毒的痘苗病毒疫苗 |
| CN116200349A (zh) * | 2023-01-18 | 2023-06-02 | 中国医学科学院病原生物学研究所 | 一种基于改良痘苗病毒天坛株的新型冠状病毒疫苗 |
| CN118240879A (zh) * | 2023-11-01 | 2024-06-25 | 上海市重大传染病和生物安全研究院 | 骨架质粒、重组质粒以及猴痘病毒颗粒和应用 |
| WO2026047314A1 (en) * | 2024-08-28 | 2026-03-05 | University Of Surrey | Recombinant vector |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0992584A3 (en) * | 1993-05-19 | 2000-06-07 | Schering Corporation | Purified mammalian FLT3 ligands and agonists and antagonists thereof |
| EP2269619A1 (en) * | 2002-08-12 | 2011-01-05 | Jennerex Biotherapeutics ULC | Methods and compositions concerning poxviruses and cancer |
| US20040247578A1 (en) * | 2002-10-15 | 2004-12-09 | University Of Pittsburgh Of Commonwealth System Of Higher Education | Methods and reagents for inducing immunity |
| CA2705869C (en) * | 2007-11-19 | 2012-10-30 | Philippe Erbs | Poxviral oncolytic vectors |
| DK3036329T3 (da) * | 2013-08-22 | 2021-01-11 | Univ Pittsburgh Commonwealth Sys Higher Education | Immunonkolytiske terapier |
| DK3169341T3 (da) * | 2014-07-16 | 2019-08-05 | Transgene Sa | Onkolytisk virus til ekspression af immun-checkpoint-modulatorer |
| CN106520778A (zh) * | 2015-09-09 | 2017-03-22 | 北京锤特生物科技有限公司 | 改造的白介素12及其在制备治疗肿瘤的药物中的用途 |
| WO2018049261A1 (en) * | 2016-09-09 | 2018-03-15 | Icellhealth Consulting Llc | Oncolytic virus expressing immune checkpoint modulators |
| MX2020007010A (es) * | 2018-01-05 | 2020-12-10 | Ottawa Hospital Res Inst | Vectores modificados de orthopoxvirus. |
-
2019
- 2019-12-20 CA CA3124287A patent/CA3124287A1/en active Pending
- 2019-12-20 AU AU2019410148A patent/AU2019410148A1/en not_active Abandoned
- 2019-12-20 KR KR1020217022872A patent/KR20210132003A/ko not_active Ceased
- 2019-12-20 MX MX2021007439A patent/MX2021007439A/es unknown
- 2019-12-20 TW TW108147116A patent/TW202039851A/zh unknown
- 2019-12-20 MX MX2021007438A patent/MX2021007438A/es unknown
- 2019-12-20 BR BR112021012078-5A patent/BR112021012078A2/pt not_active Application Discontinuation
- 2019-12-20 PE PE2021000922A patent/PE20212307A1/es unknown
- 2019-12-20 SG SG11202106460XA patent/SG11202106460XA/en unknown
- 2019-12-20 US US17/415,606 patent/US20220380799A1/en not_active Abandoned
- 2019-12-20 WO PCT/CA2019/051899 patent/WO2020124274A1/en not_active Ceased
- 2019-12-20 AU AU2019404639A patent/AU2019404639A1/en not_active Abandoned
- 2019-12-20 US US17/415,575 patent/US20220056480A1/en not_active Abandoned
- 2019-12-20 CN CN201980092788.4A patent/CN113661246A/zh active Pending
- 2019-12-20 WO PCT/CA2019/051898 patent/WO2020124273A1/en not_active Ceased
- 2019-12-20 EP EP19898487.4A patent/EP3898997A4/en not_active Withdrawn
- 2019-12-20 JP JP2021535833A patent/JP2022516006A/ja active Pending
- 2019-12-20 EP EP19899693.6A patent/EP3898998A4/en not_active Withdrawn
- 2019-12-20 CN CN201980091966.1A patent/CN113454231A/zh active Pending
- 2019-12-20 KR KR1020217022871A patent/KR20210132002A/ko not_active Ceased
- 2019-12-20 BR BR112021011730-0A patent/BR112021011730A2/pt not_active Application Discontinuation
- 2019-12-20 JP JP2021535804A patent/JP2022514420A/ja active Pending
- 2019-12-20 CA CA3124301A patent/CA3124301A1/en active Pending
-
2021
- 2021-06-17 PH PH12021551436A patent/PH12021551436A1/en unknown
- 2021-06-18 CL CL2021001646A patent/CL2021001646A1/es unknown
- 2021-06-19 IL IL284180A patent/IL284180A/en unknown
- 2021-06-20 IL IL284188A patent/IL284188A/en unknown
- 2021-07-16 CO CONC2021/0009354A patent/CO2021009354A2/es unknown
- 2021-07-20 EC ECSENADI202153474A patent/ECSP21053474A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020124273A5 (https=) | ||
| JP6983511B2 (ja) | 脳中の転移乳癌および他の癌を処置するための方法および組成物 | |
| CN111511911B (zh) | 表达特异性地识别人间皮素的细胞表面分子、il-7和ccl19的免疫活性细胞 | |
| CN105121474B9 (zh) | 融合免疫调节蛋白及其制备方法 | |
| US12291726B2 (en) | A549 host cells comprising a recombinant oncolytic adenovirus with modified E1A cancer-specific promoter | |
| JP7438552B2 (ja) | 注射用医薬品、注射用調製物、および注射用医薬品の製造における使用 | |
| WO2020037206A4 (en) | Recombinant myxoma viruses and uses thereof | |
| US11542318B2 (en) | Use of chemokine receptor CXCR5 | |
| CN103614416A (zh) | 一种携带人穿膜肽p53与GM-CSF基因的重组溶瘤腺病毒及其用途 | |
| JPWO2020124274A5 (https=) | ||
| CN110325207A (zh) | 武装溶瘤病毒 | |
| US20180360996A1 (en) | ANTI-TUMOR COMPOSITION COMPRISING GM-CSF GENE, Flt3L-TRAIL FUSION GENE, shRNA INHIBITING TGF-BETA EXPRESSION, AND shRNA INHIBITING HSP EXPRESSION | |
| CN112996909B (zh) | 表达pd-1结合蛋白的溶瘤病毒及其应用 | |
| CN117615786A (zh) | 嵌合抗原受体及其使用方法 | |
| EP3741845B1 (en) | Recombinant vaccinia virus and pharmaceutical composition comprising same | |
| JP2021522190A5 (https=) | ||
| CA2532460A1 (en) | Synthetic gene encoding human epidermal growth factor 2/neu antigen and uses thereof | |
| CN111499766B (zh) | 针对慢性淋巴细胞白血病的免疫效应细胞、其制备方法和应用 | |
| US20220213160A1 (en) | Protein heterodimer and use thereof | |
| CN1777672A (zh) | 包含具有人恒定区的肿瘤治疗性全抗体基因的重组病毒及其用途 | |
| CN114364390A (zh) | 用于治疗癌症的包含抗癌病毒、免疫检查点抑制剂和羟基脲作为活性成分的药物组合物 | |
| CN117866107A (zh) | 靶向cd5分子的嵌合抗原受体t细胞及其抗肿瘤应用 | |
| CN116059329A (zh) | 溶瘤病毒与car t细胞联合治疗血液肿瘤的方法 | |
| US20210386806A1 (en) | Anti-tumor composition | |
| WO2021115333A1 (zh) | 一种融合蛋白及表达此蛋白的工程化免疫细胞及其应用 |